147 related articles for article (PubMed ID: 24195503)
1. The role of tumor markers and biomarkers in colorectal cancer.
Lech G; Slotwinski R; Krasnodebski IW
Neoplasma; 2014; 61(1):1-8. PubMed ID: 24195503
[TBL] [Abstract][Full Text] [Related]
2. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.
Locker GY; Hamilton S; Harris J; Jessup JM; Kemeny N; Macdonald JS; Somerfield MR; Hayes DF; Bast RC;
J Clin Oncol; 2006 Nov; 24(33):5313-27. PubMed ID: 17060676
[TBL] [Abstract][Full Text] [Related]
3. Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances.
Lech G; Słotwiński R; Słodkowski M; Krasnodębski IW
World J Gastroenterol; 2016 Feb; 22(5):1745-55. PubMed ID: 26855534
[TBL] [Abstract][Full Text] [Related]
4. Normal and modified urinary nucleosides represent novel biomarkers for colorectal cancer diagnosis and surgery monitoring.
Feng B; Zheng MH; Zheng YF; Lu AG; Li JW; Wang ML; Ma JJ; Xu GW; Liu BY; Zhu ZG
J Gastroenterol Hepatol; 2005 Dec; 20(12):1913-9. PubMed ID: 16336453
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of tumor markers and an emerging perspective on colorectal cancer.
Yamashita K; Watanabe M
Cancer Sci; 2009 Feb; 100(2):195-9. PubMed ID: 19200256
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.
Custodio A; Feliu J
Crit Rev Oncol Hematol; 2013 Jan; 85(1):45-81. PubMed ID: 22647972
[TBL] [Abstract][Full Text] [Related]
7. Alu-based cell-free DNA: a potential complementary biomarker for diagnosis of colorectal cancer.
Qi J; Qian C; Shi W; Wu X; Jing R; Zhang L; Wang Z; Ju S
Clin Biochem; 2013 Jan; 46(1-2):64-9. PubMed ID: 22975639
[TBL] [Abstract][Full Text] [Related]
8. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
Chen C; Chen LQ; Yang GL; Li Y
Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
[TBL] [Abstract][Full Text] [Related]
9. Molecular markers in the treatment of metastatic colorectal cancer.
Wilson PM; Labonte MJ; Lenz HJ
Cancer J; 2010; 16(3):262-72. PubMed ID: 20526105
[TBL] [Abstract][Full Text] [Related]
10. Biomolecular markers as determinants of patients selection for adjuvant chemotherapy of sporadic colorectal cancers.
Sudoyo AW
Acta Med Indones; 2010 Jan; 42(1):45-50. PubMed ID: 20737746
[TBL] [Abstract][Full Text] [Related]
11. Cytokeratin serum biomarkers in patients with colorectal cancer.
Holdenrieder S; Stieber P; Liska V; Treska V; Topolcan O; Dreslerova J; Matejka VM; Finek J; Holubec L
Anticancer Res; 2012 May; 32(5):1971-6. PubMed ID: 22593474
[TBL] [Abstract][Full Text] [Related]
12. Expression of EGFR, Her2 predict lymph node metastasis (LNM)-associated metastasis in colorectal cancer.
Lu Y; Jingyan G; Baorong S; Peng J; Xu Y; Cai S
Cancer Biomark; 2012; 11(5):219-26. PubMed ID: 23220854
[TBL] [Abstract][Full Text] [Related]
13. Predictive molecular classifiers in colorectal cancer.
Bohanes P; LaBonte MJ; Winder T; Lenz HJ
Semin Oncol; 2011 Aug; 38(4):576-87. PubMed ID: 21810517
[TBL] [Abstract][Full Text] [Related]
14. Community compliance with carcinoembryonic antigen: follow-up of patients with colorectal cancer.
Spratlin JL; Hui D; Hanson J; Butts C; Au HJ
Clin Colorectal Cancer; 2008 Mar; 7(2):118-25. PubMed ID: 18501071
[TBL] [Abstract][Full Text] [Related]
15. Chromosome 18q deletion as a novel molecular predictor for colorectal cancer with simultaneous hepatic metastasis.
Tanaka T; Watanabe T; Kitayama J; Kanazawa T; Kazama Y; Tanaka J; Kazama S; Nagawa H
Diagn Mol Pathol; 2009 Dec; 18(4):219-25. PubMed ID: 19861895
[TBL] [Abstract][Full Text] [Related]
16. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.
Griesenberg D; Nürnberg R; Bahlo M; Klapdor R
Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of circulating galectins as colorectal cancer markers.
Watanabe M; Takemasa I; Kaneko N; Yokoyama Y; Matsuo E; Iwasa S; Mori M; Matsuura N; Monden M; Nishimura O
Oncol Rep; 2011 May; 25(5):1217-26. PubMed ID: 21369702
[TBL] [Abstract][Full Text] [Related]
18. Microsatellite instability and therapeutic consequences in colorectal cancer.
Laghi L; Malesci A
Dig Dis; 2012; 30(3):304-9. PubMed ID: 22722556
[TBL] [Abstract][Full Text] [Related]
19. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.
Boland CR; Thibodeau SN; Hamilton SR; Sidransky D; Eshleman JR; Burt RW; Meltzer SJ; Rodriguez-Bigas MA; Fodde R; Ranzani GN; Srivastava S
Cancer Res; 1998 Nov; 58(22):5248-57. PubMed ID: 9823339
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer.
Day FL; Jorissen RN; Lipton L; Mouradov D; Sakthianandeswaren A; Christie M; Li S; Tsui C; Tie J; Desai J; Xu ZZ; Molloy P; Whitehall V; Leggett BA; Jones IT; McLaughlin S; Ward RL; Hawkins NJ; Ruszkiewicz AR; Moore J; Busam D; Zhao Q; Strausberg RL; Gibbs P; Sieber OM
Clin Cancer Res; 2013 Jun; 19(12):3285-96. PubMed ID: 23633456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
